UBS Asset Management Americas Inc. Boosts Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

UBS Asset Management Americas Inc. grew its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 6.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,876 shares of the company’s stock after purchasing an additional 2,252 shares during the quarter. UBS Asset Management Americas Inc. owned approximately 0.08% of Omnicell worth $3,000,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of OMCL. Envestnet Asset Management Inc. increased its holdings in shares of Omnicell by 5.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 56,482 shares of the company’s stock valued at $4,566,000 after purchasing an additional 3,026 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Omnicell by 0.6% during the 1st quarter. Principal Financial Group Inc. now owns 492,103 shares of the company’s stock valued at $39,781,000 after purchasing an additional 2,889 shares in the last quarter. State of Tennessee Treasury Department increased its holdings in shares of Omnicell by 15.5% during the 1st quarter. State of Tennessee Treasury Department now owns 29,155 shares of the company’s stock valued at $2,357,000 after purchasing an additional 3,904 shares in the last quarter. OppenheimerFunds Inc. increased its holdings in shares of Omnicell by 40.3% during the 1st quarter. OppenheimerFunds Inc. now owns 440,006 shares of the company’s stock valued at $35,569,000 after purchasing an additional 126,437 shares in the last quarter. Finally, Granite Investment Partners LLC increased its holdings in shares of Omnicell by 27.9% during the 1st quarter. Granite Investment Partners LLC now owns 13,665 shares of the company’s stock valued at $1,105,000 after purchasing an additional 2,985 shares in the last quarter. 98.38% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ OMCL opened at $72.54 on Wednesday. The firm has a market cap of $3.02 billion, a PE ratio of 47.41, a PEG ratio of 2.86 and a beta of 1.12. The firm has a fifty day moving average of $72.38 and a 200 day moving average of $77.27. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.54 and a current ratio of 2.03. Omnicell, Inc. has a one year low of $56.96 and a one year high of $92.59.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.47 by $0.04. The company had revenue of $217.40 million during the quarter, compared to analyst estimates of $214.13 million. Omnicell had a net margin of 5.70% and a return on equity of 11.85%. The firm’s revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.46 EPS. On average, equities analysts predict that Omnicell, Inc. will post 2.05 EPS for the current fiscal year.

Several equities analysts have recently weighed in on OMCL shares. ValuEngine lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. BidaskClub lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Thursday, June 27th. Zacks Investment Research raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a report on Monday, July 29th. Finally, Craig Hallum raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a report on Friday, July 26th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Omnicell presently has a consensus rating of “Buy” and a consensus price target of $79.11.

In other news, EVP Scott Peter Seidelmann sold 1,300 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $75.17, for a total transaction of $97,721.00. Following the transaction, the executive vice president now owns 26,333 shares of the company’s stock, valued at approximately $1,979,451.61. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman Randall A. Lipps sold 5,000 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $70.30, for a total transaction of $351,500.00. Following the transaction, the chairman now directly owns 140,506 shares in the company, valued at approximately $9,877,571.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,550 shares of company stock worth $897,409. Corporate insiders own 2.77% of the company’s stock.

About Omnicell

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Featured Story: Fundamental Analysis and Choosing Stocks

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.